Scholarlink

Background <p>Fibroblast growth factor 2 (FGF2) is a canonical member of the fibroblast growth factor family with essential roles in embryonic development, tissue regeneration, and stem cell biology, where it supports pluripotency and high proliferative capacity. Consequently, FGF2 is widely used in experimental models of regeneration and stem cell maintenance; however, its rapid thermal degradation at physiological temperatures limits its practical utility and therapeutic potential. Despite the availability of stabilized variants, developing FGF2 analogs that combine exceptional thermodynamic resilience with favorable pharmacokinetic properties remains a critical challenge for stem cell research and regenerative medicine.</p> Results <p>Using a combination of consensus sequence analysis and structure-guided protein engineering, we generated novel FGF2 variants with unprecedented thermodynamic stability and optimized extracellular matrix interactions. To enhance bioavailability, we introduced mutations that reduced affinity for heparan sulfate proteoglycans, thereby limiting sequestration within the extracellular matrix. The most stable variant exhibited a denaturation temperature increase of more than 27&#xa0;°C relative to wild-type FGF2 while fully retaining mitogenic and migratory activity after 5 days of incubation at 70&#xa0;°C. This exceptional thermal stability was accompanied by markedly increased resistance to proteolytic degradation. In functional cellular models, including adipocyte differentiation and stem cell culture, an optimized long-acting variants demonstrated superior metabolic efficacy and sustained signaling, enabling a reduction in dosing frequency from daily administration to once every three days.</p> Conclusions <p>We report the development of highly stable, highly bioactive FGF2 variants that retain full receptor specificity and binding affinity even under extreme conditions. By overcoming the intrinsic instability of the wild-type protein, these engineered FGF2s may enable future stem cell expansion and regenerative therapy applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Structure–function relationship in FGF signaling: rational design of highly stable FGF2 variants and their effect on cell growth, metabolism, and survival

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月1日

查看全文
  • Karolina Baran,
  • Adolf Koudelka,
  • Katarzyna Kotowska,
  • Aleksandra A. Czyrek,
  • Deborah Beckerova,
  • Martyna Biadun,
  • Vlad-Constantin Ursachi,
  • Radoslaw Karelus,
  • Szymon Sidor,
  • Pooja Dudeja,
  • Daniel Krowarsch,
  • Vladimir Rotrekl,
  • Pavel Krejci,
  • Malgorzata Zakrzewska

摘要

Background

Fibroblast growth factor 2 (FGF2) is a canonical member of the fibroblast growth factor family with essential roles in embryonic development, tissue regeneration, and stem cell biology, where it supports pluripotency and high proliferative capacity. Consequently, FGF2 is widely used in experimental models of regeneration and stem cell maintenance; however, its rapid thermal degradation at physiological temperatures limits its practical utility and therapeutic potential. Despite the availability of stabilized variants, developing FGF2 analogs that combine exceptional thermodynamic resilience with favorable pharmacokinetic properties remains a critical challenge for stem cell research and regenerative medicine.

Results

Using a combination of consensus sequence analysis and structure-guided protein engineering, we generated novel FGF2 variants with unprecedented thermodynamic stability and optimized extracellular matrix interactions. To enhance bioavailability, we introduced mutations that reduced affinity for heparan sulfate proteoglycans, thereby limiting sequestration within the extracellular matrix. The most stable variant exhibited a denaturation temperature increase of more than 27 °C relative to wild-type FGF2 while fully retaining mitogenic and migratory activity after 5 days of incubation at 70 °C. This exceptional thermal stability was accompanied by markedly increased resistance to proteolytic degradation. In functional cellular models, including adipocyte differentiation and stem cell culture, an optimized long-acting variants demonstrated superior metabolic efficacy and sustained signaling, enabling a reduction in dosing frequency from daily administration to once every three days.

Conclusions

We report the development of highly stable, highly bioactive FGF2 variants that retain full receptor specificity and binding affinity even under extreme conditions. By overcoming the intrinsic instability of the wild-type protein, these engineered FGF2s may enable future stem cell expansion and regenerative therapy applications.